Influence of Intraoperative Blood Salvage and Autotransfusion on Tumor Recurrence After Deceased Donor Liver Transplantation

The practice of intraoperative blood salvage and autotransfusion (IBSA) during deceased donor liver transplantation (DDLT) for hepatocellular carcinoma (HCC) can potentially reduce the need for allogeneic blood transfusion. However, implementing IBSA remains debatable due to concerns about its possible detrimental effects on oncologic recurrence. Hence, a nationwide multi-center study was conducted to investigate further the association between IBSA and post-transplant HCC recurrence, including a stratified subgroup analysis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Liver Transplant; Complications

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

adult-to-adult deceased donor liver transplantation for hepatocellular carcinoma

Exclusion criteria

patients under 18 years of age
presence of extrahepatic metastasis
combined kidney transplantation
reduced-size or split liver transplantation
re-transplantation

Treatment and study plan

Primary outcomes

Postoperative recurrence of liver cancer

Time frame: 2015.1.1-2020.12.31

The overall incidence of HCC recurrence (intrahepatic or extrahepatic) after LT.

Sponsors and collaborators

Lead sponsor

Zhejiang University

Other

Collaborators

Shulan (Hangzhou) Hospital

Registry information

Important dates

Study start: 2015
Primary completion: 2020
Study completion: 2021
First posted: Mar 12, 2024
Registry last updated: Mar 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed